Cargando…

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations

BACKGROUND: The aim of this study was to detect the epidermal growth factor receptor (EGFR)-activating mutations and other oncogene alterations in patients with non-small-cell lung cancers (NSCLC) who experienced a treatment failure in response to EGFR-tyrosine kinase inhibitors (TKIs) with a next g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masago, Katsuhiro, Fujita, Shiro, Muraki, Miho, Hata, Akito, Okuda, Chiyuki, Otsuka, Kyoko, Kaji, Reiko, Takeshita, Jumpei, Kato, Ryoji, Katakami, Nobuyuki, Hirata, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647703/ https://www.ncbi.nlm.nih.gov/pubmed/26572169 http://dx.doi.org/10.1186/s12885-015-1925-2

Ejemplares similares

Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer
por: Fujita, Shiro, et al.
Publicado: (2015)

Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton System
por: Fujita, Shiro, et al.
Publicado: (2017)

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2017)

Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
por: Fujita, Shiro, et al.
Publicado: (2010)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Masago, Katsuhiro, et al.
Publicado: (2018)

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
por: Fujita, Shiro, et al.
Publicado: (2012)

Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer
por: Fujita, Shiro, et al.
Publicado: (2021)

Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment
por: Masago, Katsuhiro, et al.
Publicado: (2022)

Continuous morphine infusion for end-stage lung cancer patients
por: KIM, YOUNG HAK, et al.
Publicado: (2013)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
por: Masago, Katsuhiro, et al.
Publicado: (2010)

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Togashi, Yosuke, et al.
Publicado: (2011)

Biopsy of palliative lesions following radiotherapy
por: Fujita, Shiro, et al.
Publicado: (2019)

Optimal dilution of contrast medium for quantitating parenchymal blood volume using a flat-panel detector
por: Kuriyama, Takumi, et al.
Publicado: (2017)

Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer
por: TOGASHI, YOSUKE, et al.
Publicado: (2013)

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?
por: Hata, Akito, et al.
Publicado: (2018)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

Long-Term Recurrence of Completely Resected NSCLC
por: Masago, Katsuhiro, et al.
Publicado: (2020)

Comparison between Fluorimetry (Qubit) and Spectrophotometry (NanoDrop) in the Quantification of DNA and RNA Extracted from Frozen and FFPE Tissues from Lung Cancer Patients: A Real-World Use of Genomic Tests
por: Masago, Katsuhiro, et al.
Publicado: (2021)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
por: Ninomaru, Taira, et al.
Publicado: (2021)

Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus
por: Okuma, Yusuke, et al.
Publicado: (2014)

Targeted RNA sequencing with touch imprint cytology samples for non‐small cell lung cancer patients
por: Seto, Katsutoshi, et al.
Publicado: (2020)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
por: Kaneda, Toshihiko, et al.
Publicado: (2018)

A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
por: Tachihara, Motoko, et al.
Publicado: (2019)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Surgical perception of lower tracheal or carinal resection
por: Sugita, Yusuke, et al.
Publicado: (2021)

Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer
por: Fukuhara, Akiko, et al.
Publicado: (2010)

t(9;14)(p13;q32)/ PAX5 -IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma
por: Ohno, Hitoshi, et al.
Publicado: (2021)

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer
por: Kagawa, Yusuke, et al.
Publicado: (2020)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2(V617F)-myeloproliferative neoplasm
por: Fukutsuka, Katsuhiro, et al.
Publicado: (2021)

Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant
por: Tomida, Akimasa, et al.
Publicado: (2022)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

A case of leptomeningeal metastases of human epidermal growth factor receptor 2-positive breast cancer that responded well to lapatinib plus capecitabine
por: Nakao, Takayuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a233mjrdrugr82g62o79hdci1c